ADVANCED THERAPIES | ATMP & CRYOGENICS • 8–10 min read • Published: October 27, 2026

What Makes Cell & Gene Therapy Logistics Different?

Understanding the Specialized Transportation Requirements of Advanced Therapies

What Makes Cell & Gene Therapy Logistics Different?
RX Logistics Technical Series

Advanced Therapy Overview

Cell and gene therapies represent an unprecedented revolution in modern medicine. These advanced therapeutic medicinal products (ATMPs) involve highly complex biological manufacturing processes, living cellular materials, and exceptionally stringent logistics protocols.

Unlike mass-manufactured chemical tablets, patient-specific autologous therapies require unbroken, time-critical coordination connecting the patient's collection bed, specialized cleanroom manufacturing suites, and hospital infusion suites.

1. Understanding Cell and Gene Therapies

Cell therapies utilize living human or engineered cells to fight diseases such as oncology indications, while gene therapies introduce, modify, or replace mutated genetic material. Because these products frequently consist of living cellular structures, their viability decays rapidly if exposed to thermal stress or excessive vibration.

2. Why Advanced Therapy Logistics Is Different

Extreme Temperature Regimens

Many therapies require cryogenic vapor-phase liquid nitrogen storage at −150°C to −196°C to arrest cellular metabolism.

Time-Definite Delivery Windows

Apheresis starting materials frequently have strict 24-to-48 hour viability windows from patient collection to lab processing.

Zero Tolerance for Loss

A lost autologous batch cannot be replaced from a warehouse shelf—it belongs to a severely ill patient waiting in a hospital ward.

Strict Chain of Identity (COI)

An unbroken barcode/RFID connection guaranteeing the therapy created from Patient A is infused back into Patient A.

3. The Role of Cryogenic Dry Vapor Shippers

Cryogenic shipping is not an extension of conventional refrigerated transport. It relies on specialized Liquid Nitrogen (LN2) Dry Shippers. Inside these double-walled stainless steel dewars, hydrophobic absorbent material wicks liquid nitrogen, creating a cold, non-spillable nitrogen vapor environment maintaining −150°C or colder for up to 10–14 days.

IATA Compliance Note: Dry vapor shippers must be fully charged and inspected so no free liquid nitrogen remains, enabling them to travel under IATA Special Provision A152 as non-restricted cargo while delivering full cryogenic preservation.

4. Chain of Identity (COI) vs. Chain of Custody (COC)

Chain of Identity (COI)

Maintains the immutable link between the individual donor/patient and their unique biological therapy across every extraction, manufacturing step, label change, and hospital ward.

Chain of Custody (COC)

Records the sequential chronological transfers of physical custody: courier driver identity, security handoffs, airport tarmac escorts, temperature validations, and delivery timestamps.

5. RX Logistics' Support for Advanced Therapies

RX Logistics provides dedicated ATMP logistics coordination, validated dry vapor shipper conditioning and charging, real-time cryogenic temperature and tilt monitoring, direct tarmac handling, and 24/7 mission control oversight from apheresis collection to final bed-side infusion.

Conclusion: Supporting Next-Generation Medicine

Advanced therapy logistics is not simply about moving a product—it is about orchestrating a precision-timed, cryogenically validated journey that directly enables curative treatments for patients around the globe.

Authoritative References & Quality Standards

Compliant with standards from the Foundation for the Accreditation of Cellular Therapy (FACT) and IATA Dangerous Goods Regulations (DGR) for dry vapor shippers.

Directly Related Capability

Clinical & Advanced Therapy Logistics

Ultra-low and liquid nitrogen dry vapor shippers (-150°C and below) with strict chain of identity and time-definite flight coordination.

Explore Service
Dedicated Support Hotline

Need Shipment Planning?

Connect directly with our logistics specialists to evaluate temperatures, routes, and packaging.

+91 9063436999 Submit RFQ Enquiry

Article Information

Category:
Advanced Therapies
Publication Type:
Specialized Logistics Insights
Focus Keyword:
Cell and Gene Therapy Logistics
Estimated Reading Time:
8–10 min read
Published Date:
October 27, 2026
Back to All Insights
RELATED KNOWLEDGE

More Industry Perspectives

Cold Chain 9–11 min read

Why Temperature Integrity Matters in Pharmaceutical Logistics

Explore the critical role of temperature control in pharmaceutical transportation, including cold chain risks, specialized packaging, monitoring technologies, and quality-focused logistics practices.

October 15, 2026 Read
Visibility & Monitoring 8–10 min read

Understanding the Role of IoT Monitoring in Cold Chain

Discover how connected monitoring technologies enhance shipment visibility, support temperature-risk management, and enable informed decisions across pharmaceutical supply chains.

October 22, 2026 Read
Packaging 7–9 min read

Active vs Passive Temperature-Controlled Packaging

Understand active and passive pharmaceutical packaging, their differences, applications, and key considerations for temperature-controlled transportation.

October 24, 2026 Read
PRECISION IN MOTION

Discuss Your Logistics Requirement

Looking for specialized logistics solutions for temperature-sensitive pharmaceutical shipments, clinical trials, or advanced therapies? Connect with RX Logistics to discuss your transportation, packaging, and monitoring requirements.